Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of edasalonexent versus placebo in boys with Duchenne muscular dystrophy
MOH_2019-04-17_004903Phase 3Not yet recruiting
- Sponsor
- Astria Therapeutics
- Start
- Mar 2019
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Edasalonexent with Placebo (2 arms). Planned start Mar 2019; status: not yet recruiting.
02
Drugs
edasalonexent
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on MOH_2019-04-17_004903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-04-17_004903.